MedTrace Logo

In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm

NCT01405794 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-07-04

Study results available
· View outcomes & findings →

Summary

The investigators propose to study oral commercial silver nanoparticle products on human enzyme activity.

Conditions

  • Healthy

Interventions

DRUG

32ppm Silver Particle

Oral silver dose of 32ppm

DRUG

Placebo

Sterile Water No Silver

Sponsors & Collaborators

Principal Investigators

  • Mark Munger, Pharm.D. · University of Utah

Study Design

Allocation
NON_RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01405794 on ClinicalTrials.gov